Pathogen-specific immune fingerprints during acute infection: The diagnostic potential of human γδ t-cells

Frontiers in Immunology

Volumn 5, Issue NOV, 2014, Pages

  Eberl, Matthias ^a   Friberg, Ida M ^a   Liuzzi, Anna Rita ^a   Morgan, Matt P ^a,b   Topley, Nicholas ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

Bacterial infection; Biomarkers; Innate immunity; Local inflammation; Point of care diagnosis

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL EXTRACT; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 22; PATTERN RECOGNITION RECEPTOR; PROCALCITONIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

CD4+ T LYMPHOCYTE; DRUG USE; ESCHERICHIA COLI; GAMMA DELTA T LYMPHOCYTE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; IMMUNE RESPONSE; INFECTION; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; MONOCYTE; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL; NONHUMAN; NOTE; PERITONITIS; POLYMERASE CHAIN REACTION; SALMONELLA ENTERICA; STAPHYLOCOCCUS AUREUS; VIRUS INFECTION;

EID: 84919442784     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00572     Document Type: Note

References (64)

1. Fauci AS, Morens DM. The perpetual challenge of infectious diseases. N Engl J Med (2012) 366(5):454-61. doi: 10.1056/nejmra1108296
2. Hede K. Antibiotic resistance: an infectious arms race. Nature (2014) 509(7498):S2-3. doi:10.1038/509S2a
3. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis (2010) 10(9):597-602. doi:10.1016/S1473-3099(10)70143-2
4. Davey MS, Tyrrell JM, Howe RA, Walsh TR, Moser B, Toleman MA, et al. A promising target for treatment of multidrug-resistant bacterial infections. Antimicrob Agents Chemother (2011) 55(7):3635-6. doi:10.1128/aac.00382-11
5. Edelstein MV, Skleenova EN, Shevchenko OV, D'Souza JW, Tapalski DV, Azizov IS, et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis (2013) 13(10):867-76. doi:10.1016/S1473-3099(13)70168-3
6. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother (2009) 64(Suppl 1):i29-36. doi:10.1093/jac/dkp255
7. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century - a clinical super-challenge. N Engl J Med (2009) 360(5):439-43. doi:10.1056/nejmp0804651
8. Antimicrobial Resistance: Global Report on Surveillance 2014. World Health Organisation. (2014). Available from: http://www.who.int/drugresistance
9. Annual Epidemiological Report 2012 - Reporting on 2010 Surveillance Data and 2011 Epidemic Intelligence Data. European Centre for Disease Prevention and Control. Stockholm: ECDC (2013).
10. Antibiotic Resistance Threats in the United States, 2013. Centers for Disease Control and Prevention. (2013). Available from: http://www.cdc.gov/drugresistance/threat-report-2013
11. UK Five Year Antimicrobial Resistance Strategy2013 to 2018. UK Department of Health. (2013). Available from: https://www.gov.uk/government/publications/uk-5-year-antimicrobial-resistance-strategy-2013-to-2018
12. van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis (2008) 14(11):1722-30. doi:10.3201/eid1411.070467
13. Kanthor R. Diagnostics: detection drives defence. Nature (2014) 509(7498):S14-5. doi:10.1038/509S14a
14. Koch R. Zur Untersuchung von pathogenen Organismen. Mittheilungen aus dem Kaiserlichen Gesundheitsamte (1881) 1:1-48.
15. Shafazand S, Weinacker AB. Blood cultures in the critical care unit: improving utilization and yield. Chest (2002) 122(5):1727-36. doi:10.1378/chest.122.5.1727
16. Richards D, Toop L, Chambers S, Fletcher L. Response to antibiotics of women with symptoms of urinary tract infection but negative dipstick urine test results: double blind randomised controlled trial. BMJ (2005) 331(7509):143. doi:10.1136/bmj.38496.452581.8F
17. Fahim M, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, et al. Culture-negative peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes in 435 cases. Am J Kidney Dis (2010) 55(4):690-7. doi:10.1053/j.ajkd.2009.11.015
18. Kessel AS, Sharland M. The new UK antimicrobial resistance strategy and action plan. BMJ (2013) 346:f1601. doi:10.1136/bmj.f1601
19. Leggieri N, Rida A, François P, Schrenzel J. Molecular diagnosis of bloodstream infections: planning to (physically) reach the bedside. Curr Opin Infect Dis (2010) 23(4):311-9. doi:10.1097/qco.0b013e32833bfc44
20. Gubala V, Harris LF, Ricco AJ, Tan MX, Williams DE. Point of care diagnostics: status and future. Anal Chem (2012) 84(2):487-515. doi:10.1021/ac2030199
21. Bissonnette L, Bergeron MG. Infectious disease management through point-of-care personalized medicine molecular diagnostic technologies. J Pers Med (2012) 2(2):50-70. doi:10.3390/jpm2020050
22. Caliendo AM, Gilbert DN, Ginocchio CC, Hanson KE, May L, Quinn TC, et al. Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis (2013) 57(Suppl 3):S139-70. doi:10.1093/cid/cit578
23. Fournier PE, Drancourt M, Colson P, Rolain JM, La Scola B, Raoult D. Modern clinical microbiology: new challenges and solutions. Nat Rev Microbiol (2013) 11(8):574-85. doi:10.1038/nrmicro3068
24. Casadevall A, Pirofski LA. Host-pathogen interactions: basic concepts of microbial commensalism, colonization, infection, and disease. Infect Immun (2000) 68(12):6511-8. doi:10.1128/IAI.68.12.6511-6518.2000
25. Trautner BW. Asymptomatic bacteriuria: when the treatment is worse than the disease. Nat Rev Urol (2011) 9(2):85-93. doi:10.1038/nrurol.2011.192
26. Yu VL. Guidelines for hospital-acquired pneumonia and health-care-associated pneumonia: a vulnerability, a pitfall, and a fatal flaw. Lancet Infect Dis (2011) 11(3):248-52. doi:10.1016/S1473-3099(11)70005-6
27. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis (2007) 7(3):210-7. doi:10.1016/S1473-3099(07)70052-X
28. Lam MF, Leung JC, Lam CW, Tse KC, Lo WK, Lui SL, et al. Procalcitonin fails to differentiate inflammatory status or predict long-term outcomes in peritoneal dialysis-associated peritonitis. Perit Dial Int (2008) 28(4):377-84.
29. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care (2010) 14(1):R15. doi:10.1186/cc8872
30. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother (2011) 66(Suppl 2):ii33-40. doi:10.1093/jac/dkq523
31. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol (1989) 54(1):1-13. doi:10.1101/SQB.1989.054.01.003
32. Ramilo O, Allman W, Chung W, Mejias A, Ardura M, Glaser C. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood (2007) 109(5):2066-77. doi:10.1182/blood-2006-02-002477
33. Mejias A, Suarez NM, Ramilo O. Detecting specific infections in children through host responses: a paradigm shift. Curr Opin Infect Dis (2014) 27(3):228-35. doi:10.1097/QCO.0000000000000065
34. Lin CY, Roberts GW, Kift-Morgan A, Donovan KL, Topley N, Eberl M. Pathogen-specific local immune fingerprints diagnose bacterial infection in peritoneal dialysis patients. J Am Soc Nephrol (2013) 24(12):2002-9. doi:10.1681/asn.2013040332
35. Blander JM, Sander LE. Beyond pattern recognition: five immune checkpoints for scaling the microbial threat. Nat Rev Immunol (2012) 12(3):215-25. doi:10.1038/nri3167
36. Stuart LM, Paquette N, Boyer L. Effector-triggered versus pattern-triggered immunity: how animals sense pathogens. Nat Rev Immunol (2013) 13(3):199-206. doi:10.1038/nri3398
37. Broz P, Monack DM. Newly described pattern recognition receptors team up against intracellular pathogens. Nat Rev Immunol (2013) 13(8):551-65. doi:10.1038/nri3479
38. Sandstrom A, Peigné CM, Léger A, Crooks JE, Konczak F, Gesnel MC, et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vg9Vd2 T cells. Immunity (2014) 40(4):490-500. doi:10.1016/j.immuni.2014.03.003
39. Corbett AJ, Eckle SB, Birkinshaw RW, Liu L, Patel O, Mahony J, et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature (2014) 509(7500):361-5. doi:10.1038/nature13160
40. Bonneville M, O'Brien RL, Born WK. γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol (2010) 10(7):467-78. doi:10.1038/nri2781
41. Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol (2013) 13(2):88-100. doi:10.1038/nri3384
42. Altincicek B, Moll J, Campos N, Foerster G, Beck E, Hoeffler JF, et al. Human γδ T cells are activated by intermediates of the 2-C-methyl-d-erythritol 4-phosphate pathway of isoprenoid biosynthesis. J Immunol (2001) 166(6):3655-8. doi:10.4049/jimmunol.166.6.3655
43. Morita CT, Jin C, Sarikonda G, Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vg2Vd2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev (2007) 215(1):59-76. doi:10.1111/j.1600-065x.2006.00479.x
44. Eberl M, Moser B. Monocytes and γδ T cells: close encounters in microbial infection. Trends Immunol (2009) 30(12):562-8. doi:10.1016/j.it.2009.09.001
45. Riganti C, Massaia M, Davey MS, Eberl M. Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators? Eur J Immunol (2012) 42(7):1668-76. doi:10.1002/eji.201242492
46. Davey MS, Lin CY, Roberts GW, Heuston S, Brown AC, Chess JA, et al. Human neutrophil clearance of bacterial pathogens triggers anti-microbial γδ T cell responses in early infection. PLoS Pathog (2011) 7(5):e1002040. doi:10.1371/journal.ppat.1002040
47. Bank I, Marcu-Malina V. Quantitative peripheral blood perturbations of γδ T cells in human disease and their clinical implications. Clin Rev Allergy Immunol (2014). doi:10.1007/s12016-013-8391-x
48. Begley M, Gahan CG, Kollas AK, Hintz M, Hill C, Jomaa H, et al. The interplay between classical and alternative isoprenoid biosynthesis controls γδ T cell bioactivity of Listeria monocytogenes. FEBS Lett (2004) 561(1-3):99-104. doi:10.1016/S0014-5793(04)00131-0
49. Frencher J, Shen H, Yan L, Wilson JO, Freitag NE, Rizzo AN, et al. HMBPP-deficient Listeria mutant induces altered pulmonary/systemic responses, effector functions and memory polarization of Vg2Vd2 T cells. J Leukoc Biol (2014). doi:10.1189/jlb.6HI1213-632R
50. Puan KJ, Wang H, Dairi T, Kuzuyama T, Morita CT. fldA is an essential gene required in the 2-C-methyl-d-erythritol 4-phosphate pathway for isoprenoid biosynthesis. FEBS Lett (2005) 579(17):3802-6. doi:10.1016/j.febslet.2005.05.047
51. Brown AC, Eberl M, Crick DC, Jomaa H, Parish T. The nonmevalonate pathway of isoprenoid biosynthesis in Mycobacterium tuberculosis is essential and transcriptionally regulated by Dxs. J Bacteriol (2010) 192(9):2424-33. doi:10.1128/JB.01402-09
52. Workalemahu G, Wang H, Puan KJ, Nada MH, Kuzuyama T, Jones BD, et al. Metabolic engineering of Salmonella vaccine bacteria to boost human Vg2Vd2 T cell immunity. J Immunol (2014) 193(2):708-21. doi:10.4049/jimmunol.1302746
53. Eberl M, Roberts GW, Meuter S, Williams JD, Topley N, Moser B. A rapid crosstalk of human γδ T cells and monocytes drives the acute inflammation in bacterial infections. PLoS Pathog (2009) 5(2):e1000308. doi:10.1371/journal.ppat.1000308
54. Davey MS, Morgan MP, Liuzzi AR, Tyler CJ, Khan MWA, Szakmany T, et al. Microbe-specific unconventional T cells induce human neutrophil differentiation into antigen cross-presenting cells. J Immunol (2014) 193:3704-16. doi:10.4049/jimmunol.1401018
55. Caccamo N, Dieli F, Wesch D, Jomaa H, Eberl M. Sex-specific phenotypical and functional differences in peripheral human Vg9/Vd2 T cells. J Leukoc Biol (2006) 79(4):663-6. doi:10.1189/jlb.1105640
56. Gomes AQ, Martins DS, Silva-Santos B. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res (2010) 70(24):10024-7. doi:10.1158/0008-5472.can-10-3236
57. Moser B, Eberl M. γδ T-APCs: a novel tool for immunotherapy? Cell Mol Life Sci (2011) 68(14):2443-52. doi:10.1007/s00018-011-0706-6
58. Fisher JP, Heuijerjans J, Yan M, Gustafsson K, Anderson J. γδ T cells for cancer immunotherapy: a systematic review of clinical trials. Oncoimmunology (2014) 3(1):e27572. doi:10.4161/onci.27572
59. Saito H, Kranz DM, Takagaki Y, Hayday AC, Eisen HN, Tonegawa S. Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA sequences. Nature (1984) 309(5971):757-62. doi:10.1016/0092-8674(85)90140-0
60. Hayday AC, Saito H, Gillies SD, Kranz DM, Tanigawa G, Eisen HN, et al. Structure, organization, and somatic rearrangement of T cell gamma genes. Cell (1985) 40(2):259-69. doi:10.1016/0092-8674(85)90140-0
61. Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M, et al. Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands. Science (1994) 264(5156):267-70. doi:10.1126/science.8146660
62. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature (1995) 375(6527):155-8. doi:10.1038/375155a0
63. Welton JL, Morgan MP, Martí S, Stone MD, Moser B, Sewell AK, et al. Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial. J Bone Miner Res (2013) 28(3):464-71. doi:10.1002/jbmr.1797
64. Welton JL, Martí S, Mahdi MH, Boobier C, Barrett-Lee PJ, Eberl M. γδ T cells predict outcome in zoledronate-treated breast cancer patients. Oncologist (2013) 18(8):e22-3. doi:10.1634/theoncologist.2013-0097